AllAnalyst Report
logoMorningstarApril 01, 2021

Quest Diagnostics Incorporated: Quest Diagnostics Stays True to Its Reference Lab Course by Selling Its Share of Q2 Solutions

Symbols
DGX
Sector(s)
Healthcare
Rating
Current Price
$135.42
Fair Value
Economic Moat
Stewardship
Summary

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Debbie Wang

Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.